Clinical Trials Browser

Completed × Small Cell Lung Carcinoma × atezolizumab × Clear all

NCT04487756 2026-06-02

VENEZO-LUNG

Phase 1/2 Completed

Small Cell Lung Carcinoma

NCT04256421 2026-04-03

SKYSCRAPER-02

Phase 3 Completed

490 enrolled 33 charts

Small Cell Lung Carcinoma

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT04920981 2024-11-07

CLINATEZO

Small Cell Lung Carcinoma

NCT04622228 2024-07-29

Match

Phase 2 Completed

Small Cell Lung Carcinoma

NCT04028050 2024-07-16

MAURIS

Phase 3 Completed

Small Cell Lung Carcinoma

NCT04730999 2024-07-05

CeLEBrATE

Phase 2 Completed

Small Cell Lung Carcinoma

NCT02763579 2023-07-28

IMpower133

Phase 3 Completed

503 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03059667 2021-02-10

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

Phase 2 Completed

Small Cell Lung Carcinoma